کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2810313 | 1158428 | 2013 | 7 صفحه PDF | دانلود رایگان |

• In the liver, insulin antagonizes ApoB secretion at multiple sites.
• Insulin promotes ApoB clearance via multiple hepatic receptor systems.
• In diabetes, ApoB secretion is increased, and ApoB clearance is decreased.
• Changes in ApoB metabolism may drive cardiovascular disease in the diabetic state.
The leading cause of death in diabetic patients is cardiovascular disease. Apolipoprotein B (ApoB)-containing lipoprotein particles, which are secreted and cleared by the liver, are essential for the development of atherosclerosis. Insulin plays a key role in the regulation of ApoB. Insulin decreases ApoB secretion by promoting ApoB degradation in the hepatocyte. In parallel, insulin promotes clearance of circulating ApoB particles by the liver via the low-density lipoprotein receptor (LDLR), LDLR-related protein 1 (LRP1), and heparan sulfate proteoglycans (HSPGs). Consequently, the insulin-resistant state of type 2 diabetes (T2D) is associated with increased secretion and decreased clearance of ApoB. Here, we review the mechanisms by which insulin controls the secretion and uptake of ApoB in normal and diabetic livers.
Journal: - Volume 24, Issue 8, August 2013, Pages 391–397